| 产品描述: | Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1. |
| 靶点: |
IC50: 0.57 nM (PARP1);PARP |
| 体内研究: |
Talazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxylmethyl cellulose. Oral administration of Talazoparib elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects are also found when Talazoparib is combined with temozolomide, SN38, or platinum drugs |
| 参考文献: |
1. Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003-15. |
| 溶解性: |
DMSO : ≥ 108 mg/mL (195.46 mM) |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.81 ml |
9.049 ml |
18.098 ml |
| 5 mM |
0.362 ml |
1.81 ml |
3.62 ml |
| 10 mM |
0.181 ml |
0.905 ml |
1.81 ml |
| 50 mM |
0.036 ml |
0.181 ml |
0.362 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |